JP2014522855A5 - - Google Patents

Download PDF

Info

Publication number
JP2014522855A5
JP2014522855A5 JP2014519688A JP2014519688A JP2014522855A5 JP 2014522855 A5 JP2014522855 A5 JP 2014522855A5 JP 2014519688 A JP2014519688 A JP 2014519688A JP 2014519688 A JP2014519688 A JP 2014519688A JP 2014522855 A5 JP2014522855 A5 JP 2014522855A5
Authority
JP
Japan
Prior art keywords
piperidin
oxo
benzoyl
pyrrolidin
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014519688A
Other languages
English (en)
Japanese (ja)
Other versions
JP5957077B2 (ja
JP2014522855A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2012/053613 external-priority patent/WO2013008217A1/en
Publication of JP2014522855A publication Critical patent/JP2014522855A/ja
Publication of JP2014522855A5 publication Critical patent/JP2014522855A5/ja
Application granted granted Critical
Publication of JP5957077B2 publication Critical patent/JP5957077B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014519688A 2011-07-13 2012-07-13 タンキラーゼ阻害剤として使用するための4−ピペリジニル化合物 Expired - Fee Related JP5957077B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161507321P 2011-07-13 2011-07-13
US61/507,321 2011-07-13
PCT/IB2012/053613 WO2013008217A1 (en) 2011-07-13 2012-07-13 4 - piperidinyl compounds for use as tankyrase inhibitors

Publications (3)

Publication Number Publication Date
JP2014522855A JP2014522855A (ja) 2014-09-08
JP2014522855A5 true JP2014522855A5 (enExample) 2015-08-06
JP5957077B2 JP5957077B2 (ja) 2016-07-27

Family

ID=46604017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014519688A Expired - Fee Related JP5957077B2 (ja) 2011-07-13 2012-07-13 タンキラーゼ阻害剤として使用するための4−ピペリジニル化合物

Country Status (21)

Country Link
US (2) USRE46942E1 (enExample)
EP (1) EP2731940B1 (enExample)
JP (1) JP5957077B2 (enExample)
KR (1) KR20140051944A (enExample)
CN (1) CN103797006B (enExample)
AP (1) AP2014007400A0 (enExample)
AU (1) AU2012282076A1 (enExample)
BR (1) BR112014000792A2 (enExample)
CA (1) CA2841932A1 (enExample)
CO (1) CO6880065A2 (enExample)
CR (1) CR20140071A (enExample)
DO (1) DOP2014000012A (enExample)
EA (1) EA201490272A1 (enExample)
ES (1) ES2548513T3 (enExample)
IL (1) IL230430A0 (enExample)
MA (1) MA35342B1 (enExample)
MX (1) MX2014000536A (enExample)
PH (1) PH12014500126A1 (enExample)
TN (1) TN2014000016A1 (enExample)
WO (1) WO2013008217A1 (enExample)
ZA (1) ZA201400374B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181266B2 (en) * 2011-07-13 2015-11-10 Novartis Ag 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
RU2696572C2 (ru) 2012-03-07 2019-08-05 Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение
TW201524952A (zh) * 2013-03-15 2015-07-01 Araxes Pharma Llc Kras g12c之共價抑制劑
HUE037134T2 (hu) * 2013-08-07 2018-08-28 Merck Patent Gmbh Piperidin-karbamid-származékok
CA2922469A1 (en) 2013-09-11 2015-03-19 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
CN105793264B (zh) * 2014-03-10 2017-09-01 四川海思科制药有限公司 取代的二氢苯并呋喃‑哌啶‑甲酮衍生物、其制备及用途
RU2016147727A (ru) 2014-05-07 2018-06-08 Мерк Патент Гмбх Гетероциклилбутанамидные производные
KR20160007347A (ko) 2014-07-11 2016-01-20 에스티팜 주식회사 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도
KR101739003B1 (ko) 2014-07-11 2017-05-23 에스티팜 주식회사 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
WO2016006974A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
CA3003600A1 (en) * 2015-11-02 2017-05-11 Merck Patent Gmbh 1,4-dicarbonyl-piperidyl derivatives
KR101777475B1 (ko) * 2015-12-08 2017-09-11 에스티팜 주식회사 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
KR102736865B1 (ko) 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
JP2022510368A (ja) 2018-12-03 2022-01-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング タンキラーゼのインヒビターとしての4-ヘテロアリールカルボニル-n-(フェニルまたはヘテロアリール)ピペリジン-1-カルボキサミド
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ras病、及び線維性疾患の処置のためのrasスーパーファミリーと相互作用する化合物
AU2020328598B2 (en) * 2019-08-15 2026-07-02 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
US20240041859A1 (en) * 2020-12-03 2024-02-08 Washington University Methods of treating and preventing kidney disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
EP1142881A4 (en) 1999-01-14 2003-05-07 Meiji Seika Kaisha POLY (ADP-RIBOSE) POLYMERASE INHIBITORS CONSISTING OF PYRIMIDINE DERIVATIVES
US6710058B2 (en) * 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DE10056312A1 (de) 2000-11-14 2002-05-16 Bayer Ag Substituierte Amidoalkyluracile und ihre Verwendung
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
US20040176361A1 (en) 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
DE10201240A1 (de) 2002-01-15 2003-07-24 Bayer Ag Substituierte Alkyluracile und ihre Verwendung
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
KR100663147B1 (ko) 2002-02-19 2007-02-28 오노 야꾸힝 고교 가부시키가이샤 축합 피리다진 유도체 화합물 및 이를 유효 성분으로서함유하는 약제
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
ATE440825T1 (de) 2003-06-06 2009-09-15 Vertex Pharma Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
CL2004002050A1 (es) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
EP1692112A4 (en) 2003-12-08 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS
GB0405101D0 (en) * 2004-03-06 2004-04-07 Astrazeneca Ab Compounds
US7375102B2 (en) 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
CA2568835C (en) * 2004-06-30 2014-05-27 Janssen Pharmaceutica N.V. Quinazolinone derivatives as parp inhibitors
WO2006028958A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE602006015658D1 (de) 2005-06-27 2010-09-02 Amgen Inc Entzündungshemmende arylnitrilverbindungen
EP2021337B1 (en) * 2006-04-25 2010-01-13 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
AU2008324203A1 (en) 2007-11-05 2009-05-14 Novartis Ag Methods and compositions for measuring Wnt activation and for treating Wnt-related cancers
KR101179753B1 (ko) 2007-11-06 2012-09-04 제일약품주식회사 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
DK2271626T3 (en) 2008-03-27 2015-02-23 Janssen Pharmaceutica Nv TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS INHIBITORS OF POLYMERIZATION OF PARP AND TUBULIN
US9181266B2 (en) * 2011-07-13 2015-11-10 Novartis Ag 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors

Similar Documents

Publication Publication Date Title
TWI868441B (zh) 非環氧氮呯化合物及其用途
JP7654071B2 (ja) 複素環スピロ化合物及び使用方法
EP4281078A1 (en) Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer
US9556197B2 (en) Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
JP2015500332A5 (enExample)
RU2018134981A (ru) Конъюгаты, содержащие ингибиторы RIPK2
US20200172546A1 (en) Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
JP2020514267A5 (enExample)
JP2011527684A5 (enExample)
JP2016531874A5 (enExample)
JP2018500376A5 (enExample)
RU2019115115A (ru) Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7
RU2009125024A (ru) Соединения замещенных диазепанов в качестве антагонистов орексиновых рецепторов
HRP20190947T1 (hr) Heterociklički spoj
HRP20230595T1 (hr) Inhibitori lizina specifične demetilaze-1
AU2023220657A1 (en) Pharmaceutical compound
JP2015522002A5 (enExample)
JP2019514878A5 (enExample)
JP2015511245A5 (enExample)
HRP20150868T1 (hr) Derivati kinolina i kinoksalina kao inhibitori kinaze
JP2017510576A5 (enExample)
JP2011522866A5 (enExample)
HRP20170484T1 (hr) Novi kondenzirani spojevi piridina kao inhibitori kazeinske kinaze
JP2013515729A5 (enExample)
JP2013500975A5 (enExample)